Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis

Abstract

Background: Survivin belongs to the protein family of inhibitors of apoptosis (IAP) and is a regulator of the cell cycle and apoptosis. The aim of this study was to assess the clinical and prognostic significance of expression survivin in patients with ovarian cancer. Methods: We systematically searched for articles in PubMed, the American Chemical Society (Publications), Medline, the Royal Society of Chemistry, Scopus and the Web of Science. Patient clinical data, overall survival (OS), disease-free survival (DFS), and survivin expression were extracted from individual studies. We performed statistical analysis using the STATA 16 package. Eighteen publications containing data from 2233 patients with ovarian cancer were included in this meta-analysis. Results: We found an adverse effect of survivin expression on OS (risk ratio (HR): 1.60; 95% confidence interval (CI): 1.33–1.93, p = 0.00) but this was not observed on DFS (HR: 1.06; 95% CI: 0.55–2.05, p = 0.87). The analysis of clinicopathological parameters showed that survivin expression was associated with the histological grades (G1–2 vs. G3) (odds ratio (OR) = 0.53, 95% CI: 0.34–0.83, p = 0.01) and: International Federation Gynecology and Obstetrics (FIGO) stage (I–II vs. III–IV) (OR = 0.22, 95% CI: 0.09–0.55, p = 0.00), but it was not significantly correlated with the histological subtype (OR = 1.14, 95% CI: 0.83–1.58, p = 0.42). Conclusions: Our meta-analysis suggests that survivin expression may be a marker of poor prognosis in ovarian cancer. Survivin expression was associated with parameters of greater aggressiveness of ovarian cancer. Prospective studies are needed to confirm our results indicating that survivin expression can be used as an ovarian cancer biomarker.

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

“…The results of the correlation analysis of clinical features showed that the expression level of ARRDC2 in OV increased with increasing FIGO stage and was highly expressed in Asian race groups ( Figures 1D,E ). And numerous studies have confirmed that the higher the FIGO stage, the worse the prognosis ( Gąsowska-Bajger et al, 2021 ). In view of the above phenomena, it was of interest to us whether ARRDC2 might contribute to the poor prognosis of OV patients.…”

A Novel Prognostic Biomarker ARRDC2 has Potential to Define Tumor Microenvironment in Ovarian Cancer

“…The results of the correlation analysis of clinical features showed that the expression level of ARRDC2 in OV increased with increasing FIGO stage and was highly expressed in Asian race groups (Figure 1E-F). And numerous studies have con rmed that the higher the FIGO stage, the worse the prognosis (12). In view of the above phenomena, it was of interest to us whether ARRDC2 might contribute to the poor prognosis of OV patients.…”

Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis

“…Several circulating molecules have been identified as possible disease markers (i.e., osteoprotegerin, survivin, metalloproteinases) [ 92 , 93 , 94 ], however, considering the recent updates from literature, we can define HE4 not only as a diagnostic, prognostic and predictive circulating biomarker, but we can refer to HE4 as a biological agent effectively involved in many of OC tumorigenesis mechanisms. Indeed, there are several OC oncogenic pathways in which HE4 plays an important role: in the light of this new perspective, we can consider this protein as a valuable tool in aiding the current transition towards “personalized oncology”.…”